 ADC Therapeutics SA NYSE:ADCT, a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generation antibody drug conjugates ADCs with highly potent and targeted pyrrolobenzodiazepine PBD dimer technology, today announced that the U.S. Food and Drug Administration FDA has lifted the partial clinical hold on the pivotal Phase 2 clinical trial of camidanlumab tesirine Cami, formerly ADCT-301 in patients with relapsed or refractory Hodgkin lymphoma HL. 